MEDICAL APPLICATIONS - NOT ONLY BILIRUBIN, BUT ALSO....
(Taken from the most recent 10K dated 3/31/98)
The Company has developed Intellectual Properties which it believes are capable of detecting and monitoring certain chromogenic diseases and disorders which are defined by the Company as those which are diagnosed or monitored by the coloration of human skin, tissue or fluid being affected ("Chromogenic Diseases").....
......In addition to its FDA-cleared device for the monitoring of bilirubin infant jaundice, the Company believes that the Intellectual Properties and Colormate(TM) System have commercial applications in (i) health care relating to the non-invasive detection and monitoring of certain Chromogenic Diseases, such as skin diseases, tuberculosis and anemia,
.......From February 1993 to June 1995, the Company conducted a feasibility study for clinical tests at Elmhurst Hospital for use of its technology in the diagnosis of tuberculosis through the measurement of skin color. The Company stopped such studies in order to focus its limited resources on the more advanced Bilirubin Project and its long-range business plan to commercialize that application......
......bilirubin infant jaundice, dermatological diseases and tuberculosis, the principle diseases for which the Company intends to market or develop commercial applications for its technologies.......
The Company is engaged in ongoing research and development relating to additional potential medical applications of its Intellectual Properties, has completed feasibility studies with Dr. Mark Lebwohl, Professor and Chairman, Department of Dermatology in New York City, and pending IRB approval from Mt. Sinai Hospital intends to commence clinical trials of the Colormate(TM) System for dermatological use in determining the appropriate levels of phototherapy to treat various skin diseases and patient tolerance for such levels of phototherapy by quantifying the amount of pigmentation and hence, photo-protection in the skin of patients.
This dermatological application of the Company's proprietary technology and device would be for patients of all ages and would be used in determining dosages of ultra violet light (phototherapy treatment) used to treat patients for a variety of diseases including psoriasis, excema, cutaneous T-cell lymphoma, vitiligo, and others. Post inflammatory hyperpigmentation also would be a condition subject to monitoring by the Colormate(TM) System........
........Over the years, the Company has developed its Intellectual Properties and Colormate(TM) System for the
(i) scientific measurement and classification of human skin color,
(ii) scientific measurements of human hair, tooth, tissue and/or fluid color,
(iii)scientific color coordination of such skin, hair, tooth and/or fluid color classification in relation to products,
(iii) scientific measurement, classification and color-oriented organization of various color sensitive consumer products, such as cosmetics, hair coloring, hosiery, clothing, tooth
enamel, paint, and textiles,
(iv) scientific color measurement in detecting and monitoring Chromogenic Diseases such as hyperbilirubinemia, and
(v) scientific color coordination of products in relation to other products.
The Company determines such scientific product color classifications by conducting laboratory product chromaticity studies. |
